-

MEDISCA and Fellow Industry Leaders Lobby for Revisions to Compounded Expiry Dates and Succeed

MASCOT, Australia--(BUSINESS WIRE)--Over the last several months, Medisca Australia along with other industry leaders have been actively putting forward to the Australian Pharmaceutical Formulary & Handbook (APF), scientific rationale for longer expiry dates for compounded preparations. Medisca is now pleased to see the efforts of the compounding community come to fruition.

In January 2021, the APF published revised standards where, in the absence of an APF formulary or stability study, compounding pharmacies are restricted to applying up to 28-day expiry dates on all compounded dosage forms, including capsules and powders that have historically received up to 6 months dating. A 28-day expiry date restriction on capsules and powders has the potential to drastically impact compounding pharmacy workflow efficiencies, cost to prepare medications, and most importantly, patient access to much needed personalised medications.

“Upon receiving the news of the change in capsule dating, we quickly ramped up efforts alongside fellow industry leaders and compounding pharmacies to express our concerns to the APF. Not only did the APF listen to us, they acted for us and, ultimately, the patients compounding pharmacy serves,” said Andrew Harb, General Manager for Medisca Australia and Emerging Markets. “The efforts of the last several months demonstrated what it means to be a community – and I and the Medisca team could not be prouder to be a part of it.”

After months of discussions and deliberations, effective as of 10 August 2021, the APF has revised the expiry date of compounded capsules and powders from up to 28 days to up to 6 months. This dating is applicable to capsules and powders that contain ingredients that are stable in air and not hygroscopic or deliquescent. This expiry date guidance is also applicable in the absence of an APF formula or stability study.

For additional support on how to assign an expiry date and access to a databank of stability-indicating studies for extended expiry dating visit: www.medisca.com.au/expiry-date.

About MEDISCA

MEDISCA is the leader in providing turnkey solutions to the pharmaceutical compounding industry and allied health care professionals worldwide. Committed to being a complete resource for prescribers, pharmacists and pharmacy technicians engaged in personalised medicine, MEDISCA offers high quality products, industry-leading support, and first-class education through its partner LP3 Network. Founded in 1989, the company has locations in Canada, the United States and Australia, optimising its service to the international market. For more information about MEDISCA, please visit www.medisca.com.au and follow us on Twitter at @medisca.

Contacts

Andrew Harb
Unit 7, Heritage Business Park
5-9 Ricketty Street, Mascot
NSW 2020, Australia
Medisca.com.au
1300 786 392

MEDISCA


Release Versions

Contacts

Andrew Harb
Unit 7, Heritage Business Park
5-9 Ricketty Street, Mascot
NSW 2020, Australia
Medisca.com.au
1300 786 392

Social Media Profiles
More News From MEDISCA

Medisca Secures Settlement With FlackTek, Reinforcing Patent Strength of MAZ® Mixer

PLATTSBURGH, N.Y.--(BUSINESS WIRE)--Medisca and FlackTek have reached a settlement to resolve their patent dispute relating to the Medisca MAZ® mixer and related mixing technologies set forth in Medisca U.S. patent numbers 10,420,705, 10,765,600, 11,090,224, 11,096,864, 10,231,903, and 10,993,876. The confidential settlement resolves the pending litigation. “This settlement validates the investment Medisca has made over the past decade in the MAZ innovation and technology,” said Sanjay Goorachu...

Medisca Statement on Settlement With Department of Justice

PLATTSBURGH, N.Y.--(BUSINESS WIRE)--Medisca Inc. has reached an agreement with the United States Department of Justice (DOJ) to resolve and terminate a civil investigation that began 9 years ago. The allegations made by the DOJ relate to the accuracy of the company’s disclosure of average wholesale prices (AWPs) for certain pharmaceutical ingredients from January 2012 to May 2015, and the reimbursement by the TRICARE program of pharmacies that purchased these ingredients at a price lower than t...

Medisca Opens New Pharmaceutical Repackaging Facility to Meet Global Demands in Personalized Medicine

PLATTSBURGH, N.Y.--(BUSINESS WIRE)--Medisca, a global leader in personalized pharmaceutical solutions, held a grand opening event on June 20, 2024, for their new repackaging and distribution facility in Plattsburgh, New York. The event was celebrated in the company of Medisca’s valued Plattsburgh team, business partners, and state and federal officials, including Congresswoman Elise Stefanik, Senator Dan Stec, and Assemblyman Billy Jones. "This event marks the completion of the largest project...
Back to Newsroom